Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial

@article{Zhang2020ImmunogenicityAS,
  title={Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial},
  author={Y. Zhang and G. Zeng and H-X Pan and C. Li and B. Kan and Y-L Hu and H. Y. Mao and Q.-Q. Xin and K. Chu and W.-X. Han and Z. Chen and R. Tang and W.-D. Yin and X. Chen and X. Gong and C. Qin and Y.-S. Hu and X-Y Liu and G.-L. Cui and C. Jiang and H-m Zhang and J. Li and M.-N. Yang and X.-J. Lian and Y. Song and J. Lu and X. Wang and M. Xu and Q. Gao and F. Zhu},
  journal={medRxiv},
  year={2020}
}
  • Y. Zhang, G. Zeng, +27 authors F. Zhu
  • Published 2020
  • Medicine
  • medRxiv
  • BACKGROUND The top priority for the control of COVID-19 pandemic currently is the development of a vaccine. A phase 2 trial conducted to further evaluate the immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac). METHODS We conducted a randomized, double-blind, placebo-controlled trial to evaluate the optimal dose, immunogenicity and safety of the CoronaVac. A total of 600 healthy adults aged 18-59 years were randomly assigned to receive 2 injections of the trial vaccine at… CONTINUE READING
    6 Citations
    SARS-CoV-2 vaccines in development
    • 25
    • PDF
    A systematic review of SARS-CoV-2 vaccine candidates
    • 4
    • PDF
    Vaccines for COVID‐19
    • 4
    Cellular immune response to SARS-CoV-2 infection in humans: a systematic review
    • 2
    • PDF

    References

    SHOWING 1-10 OF 16 REFERENCES
    Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial.
    • B. Hao, Z. Chen, +12 authors J. Huang
    • Medicine
    • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
    • 2019
    • 2
    Development of an inactivated vaccine candidate for SARS-CoV-2
    • 244
    • PDF
    An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
    • 217
    Disappearance of antibodies to SARS-associated coronavirus after recovery.
    • 132
    Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
    • 3,600
    • PDF